Latest Conference Articles

Research highlights promising advancements in renal cell carcinoma treatments, focusing on HIF-2α inhibitors and combination therapies for improved patient outcomes.

Avelumab shows modest, durable responses in advanced penile cancer, highlighting the need for innovative treatments in this challenging patient population.

A phase 2 trial reveals single-dose carboplatin plus radiotherapy offers exceptional long-term survival and minimal toxicity for stage IIa/b seminoma patients.

Experts discuss the evolving strategies in managing immune-related adverse events in cancer treatment, emphasizing precision immunomedicine and patient history.

New research reveals that radiotherapy benefits prostate cancer patients with fewer metastases, refining treatment strategies for advanced cases.

A groundbreaking study reveals that less frequent dosing of pasritamig enhances immune response in advanced prostate cancer, challenging traditional treatment assumptions.

Discover evolving strategies for managing immune-related adverse events in cancer immunotherapy, enhancing decision-making for oncologists and practitioners.

Experts discuss the need for global collaboration to enhance cancer care in rural areas, addressing access, workforce challenges, and diverse patient needs.

Recent trials at ESMO Congress 2025 clarify treatment options for metastatic renal cell carcinoma, highlighting promising combinations and emerging therapies.

Join the 43rd Annual Chemotherapy Foundation Symposium in New York City for cutting-edge cancer care education and networking opportunities.

Innovations in cancer immunotherapy highlight the urgent need for effective management of immune-related toxicities, emphasizing precision medicine and interdisciplinary collaboration.

A study reveals that lower KIM-1 levels predict better outcomes in advanced renal cell carcinoma patients treated with nivolumab and ipilimumab.

Dr. Strosberg discusses the safety profile and long-term toxicities of 212Pb-DOTAMTATE treatment, highlighting renal issues and achalasia in patients.

New research identifies CD8+ PD-1+ TIM-3– LAG-3– TILs as promising biomarkers for improved outcomes in metastatic clear cell renal cell carcinoma treatments.

Dr. Michael Soulen discusses safety concerns and adverse events in neuroendocrine tumor treatments, highlighting cytopenia and radiation risks while ensuring patient safety.

The DISCUS trial reveals that shorter systemic therapy improves quality of life for advanced urothelial cancer patients, challenging traditional treatment durations.

Nivolumab combined with visugromab demonstrates enhanced efficacy and tolerability in treating muscle-invasive bladder cancer, outperforming placebo in a recent trial.

A novel treatment combining chemotherapy and PRRT shows promising safety and efficacy for neuroendocrine tumors, with high response rates and ongoing trials.

Neoadjuvant gemcitabine plus cetrelimab shows promising pCR and RFS rates in muscle-invasive bladder cancer, highlighting new treatment options.

Lutetium Lu 177 vipivotide tetraxetan significantly enhances survival in metastatic hormone-sensitive prostate cancer when combined with standard therapies, according to recent trial results.

A novel combination therapy shows promise for preserving kidneys in high-risk upper tract urothelial carcinoma, challenging traditional treatment methods.

Experts explore a novel combined therapy for liver-dominant neuroendocrine tumors, enhancing treatment durability with chemotherapy and PRRT.

Dr. Jonathan Strosberg discusses the promising results of the ALPHAMEDIX-02 trial, evaluating a new therapy for advanced neuroendocrine tumors.

Novel approaches in MDS focus on HMA doublets, but transplant remains the only curative option to date.

Vivek Subbiah emphasizes tumor-agnostic therapies' potential to revolutionize cancer treatment by targeting genetic biomarkers, ensuring equitable access to precision medicine.

Experts discuss the importance of collaboration in improving surgical standards and treatment outcomes for neuroendocrine tumors through the CUTNETs initiative.

Healthcare professionals adjust octreotide and lanreotide doses for effective symptom control in patients with carcinoid syndrome, following NCCN guidelines.

Mary Maluccio, MD, MPH, FACS, discusses the promising next steps for 212Pb-DOTAMTATE in treating GEP-NETs, including a pivotal phase 3 trial and ongoing patient follow-up.

Dr Mary Maluccio discusses promising results and safety concerns from the ALPHAMEDIX-02 trial on innovative therapy for GEP-NETs.